Georges Weryha

Georges Weryha

Auto-generated profile, based on publicly available information

Georges Weryha

Service d’Endocrinologie, CHU de Nancy

Research Focus & Metrics

Academic Career Length

37Years (1990-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 March 2009 in New England Journal of Medicine
Verified
Journal Article
Closed access
PDF file
DLDiana Lourenço
Diana Lourenço
RBRaja Brauner
Raja Brauner
LLLin Lin
Lin Lin
APArantzazu De Perdigo
Arantzazu De Perdigo
GWGeorges Weryha
Georges Weryha
ABAnu Bashamboo
Anu Bashamboo
The genetic causes of nonsyndromic ovarian insufficiency are largely unknown. A nuclear receptor, NR5A1 (also called steroidogenic factor 1), is a key transcriptional regulator of genes involved in the hypothalamic–pituitary–steroidogenic axis. Mutation of NR5A1 causes 46,XY disorders of sex development, with or without adrenal failure, but growing experimental evidence from studies in mice suggests a key role for this factor in ovarian development and function as well. To test the hypothesis that mutations in NR5A1 cause disorders of ovarian development and function, we sequenced NR5A1 in four families with histories of both 46,XY disorders of sex development and 46,XX primary ovarian insufficiency and in 25 subjects with sporadic ovarian insufficiency. None of the affected subjects had clinical signs of adrenal insufficiency. Members of each of the four families and 2 of the 25 subjects with isolated ovarian insufficiency carried mutations in the NR5A1 gene. In-frame deletions and frameshift and missense mutations were detected. Functional studies indicated that these mutations substantially impaired NR5A1 transactivational activity. Mutations were associated with a range of ovarian anomalies, including 46,XX gonadal dysgenesis and 46,XX primary ovarian insufficiency. We did not observe these mutations in more than 700 control alleles. NR5A1 mutations are associated with 46,XX primary ovarian insufficiency and 46,XY disorders of sex development.

6 February 2013 in Current Medical Research and Opinion
Verified
Journal Article
Closed access
RRRene Rizzoli
Rene Rizzoli
SBS. Boonen
S. Boonen
Maria Luisa BrandiMaria Luisa Brandi
Maria Luisa Brandi
Olivier BruyèreOlivier Bruyère
Olivier Bruyère
CCC. Cooper
C. Cooper
JRJ.-Y. Reginster
J.-Y. Reginster
(2013). Vitamin D supplementation in elderly or postmenopausal women: a 2013 update of the 2008 recommendations from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) Current Medical Research and Opinion: Vol. 29, No. 4, pp. 305-313.

13 September 2010 in Journal of Bone and Mineral Research
Verified
Journal Article
Closed access
PDF file
RERichard Eastell
Richard Eastell
CCClaus Christiansen
Claus Christiansen
AGAndreas Grauer
Andreas Grauer
SKStepan Kutilek
Stepan Kutilek
CLCesar Libanati
Cesar Libanati
SCSteve R Cummings
Steve R Cummings

1 March 2008 in Endocrine-Related Cancer
Verified
Journal Article
Closed access
PDF file
MMM M Muresan
M M Muresan
POP Olivier
P Olivier
JLJ Leclere
J Leclere
FSF Sirveaux
F Sirveaux
LBLaurent Brunaud
Laurent Brunaud
GWG Weryha
G Weryha
The presence of distant metastases from differentiated thyroid carcinoma decreases the 10-year survival of patients by 50%. Bone metastases represent a frequent complication especially of follicular thyroid cancer and severely reduce the quality of life causing pain, fractures, and spinal cord compression. Diagnosis is established by correlating clinical suspicion with imaging. Imaging is essential to detect, localize, and assess the extension of the lesions and should be used in conjunction with clinical evidence. Bone metastases are typically associated with elevated markers of bone turnover, but these markers have not been evaluated in differentiated thyroid cancer. Skeletal and whole-body magnetic resonance imaging and fusion 2-deoxy-2-[18F]fluoro-d-glucose whole-body positron emission tomography/computed tomography (PET/CT) are the best anatomic and functional imaging techniques available in specialized centers. For well-differentiated lesions, iodine-PET scan combined 124I-PET/CT is the newest imaging development and 131I is the first line of treatment. Bisphosphonates reduce the complications rate and pain, alone or in combination with radioiodine, radionuclides, or external beam radiotherapy and should be employed. Surgery and novel minimally invasive consolidation techniques demand an appropriate patient selection for best results on a multimodal approach. Basic research on interactions between tumor cells and bone microenvironment are identifying potential novel targets for future more effective therapeutic interventions for less differentiated tumors.

1 April 2008 in The American Journal of Surgery
Verified
Journal Article
Closed access
LBLaurent Brunaud
Laurent Brunaud
LBLaurent Bresler
Laurent Bresler
AAAhmet Ayav
Ahmet Ayav
RZRasa Zarnegar
Rasa Zarnegar
ARAnne-Laure Raphoz
Anne-Laure Raphoz
PBPatrick Boissel
Patrick Boissel

1 May 2014 in The Lancet Oncology
Verified
Journal Article
Closed access
FCFrederic Castinetti
Frederic Castinetti
XQXiao-Ping Qi
Xiao-Ping Qi
MWMartin K Walz
Martin K Walz
AMAna Luiza Maia
Ana Luiza Maia
GSGabriela Sansó
Gabriela Sansó
HNHartmut P H Neumann
Hartmut P H Neumann